Advertisement

Arthritis Research & Therapy

, 20:271 | Cite as

Correction to: Incidence of giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study

  • L. K. Brekke
  • A. P. Diamantopoulos
  • B.-T. Fevang
  • J. Aβmus
  • E. Esperø
  • C. G. Gjesdal
Open Access
Correction
  • 64 Downloads

Correction to: Arthritis Res Ther (2017) 19:278

https://doi.org/10.1186/s13075-017-1479-6

Following publication of the original article [1], the authors reported an error. The incorrect sex-specific incidences of GCA were published. The correct mean annual cumulative incidence was 22.0 (95% CI 20.6–23.5) for women and 10.5 (95% CI 9.5–11.5) for men; p-value < 0.001 unaffected by the error. Revised versions of Fig. 2 and Table 2 are provided in this correction. Additionally, in the results section (page 4, first section) we report results of a sub-analysis of an extended cohort (n = 881). The correct annual cumulative incidence for women in this group was 24.1 and for men 11.6.
Fig. 2

Annual cumulative incidence of giant cell arteritis (American College of Rheumatology (ACR) criteria fulfilled) in Bergen health area 1972–2012. Overall and ESR-specific cumulative incidence calculated as cases per 100,000 general population over the age of 50 years. Incidence by sex was calculated per 100,000 women or men, respectively, and incidence by the different age categories was calculated per 100,000 population of the same age categories (< 60 years, 60–69 years, 70–79 years and 80+ years). Points plotted represent raw incidence. Solid lines were estimated using the smoothing technique of a moving average of 5 years. ESR, erythrocyte sedimentation rate

Table 2

The incidence of giant cell arteritis (GCA) in Bergen health area 1972–2012

a Mean annual cumulative incidence

 

All time

1972–1992

1993–2012

Cumulative incidence

95% CI

Cumulative incidence

95% CI

Cumulative incidence

95% CI

All patients

16.7

(15.5, 18.0)

11.2

(9.8, 12.7)

22.5

(20.5, 24.7)

Sex

 Female

22.0

(20.6, 23.5)

13.3

(11.8, 14.9)

31.2

(28.8, 33.7)

 Male

10.5

(9.5, 11.5)

8.6

(7.4, 9.9)

12.4

(10.9, 14.0)

Age, years

  < 60

2.8

(2.3, 3.3)

1.5

(1.0, 2.1)

4.1

(3.3, 5.0)

 60–69

15.5

(14.4, 16.8)

10.9

(9.6, 12.4)

20.3

(18.4, 22.4)

 70–79

34.5

(32.8, 36.4)

23.4

(21.4, 25.6)

46.2

(43.3, 49.2)

 80+

26.8

(25.3, 28.4)

14.3

(12.8, 16.0)

39.9

(37.2, 42.7)

ESR, mm/hr

 ESR < 85

8.2

(7.3, 9.1)

4.5

(3.7, 5.5)

12.0

(10.6, 13.6)

 ESR > 85

8.4

(7.6, 9.3)

6.6

(5.5, 7.7)

10.4

(9.0, 11.8)

b Relative risk (RR) according to time, sex, age and ESR

 

1972–1992

1993–2012

RR

95% CI

p-value

RR

95% CI

p-value

Unadjusted

 Time (years)

1.1

(1.1, 1.1)

< 0.001

1.0

(1.0, 1.0)

0.543

Sex

 Time (years)

1.1

(1.1, 1.1)

< 0.001

1.0

(1.0, 1.0)

0.462

 Sex (Male vs. Female)

0.6

(0.5, 0.8)

< 0.001

0.4

(0.3, 0.5)

< 0.001

Age

 Time (years)

1.1

(1.1, 1.1)

< 0.001

1.0

(1.0, 1.0)

0.135

 60–69 vs. < 60

7.2

(5.1, 10.6)

< 0.001

5.0

(3.9, 6.4)

< 0.001

 70–79 vs. < 60

15.4

(11.0, 22.5)

< 0.001

11.3

(9.1, 14.3)

< 0.001

 80+ vs. < 60

9.5

(6.7, 13.9)

< 0.001

9.8

(7.8, 12.4)

< 0.001

ESR

 Time (years)

1.1

(1.1, 1.1)

< 0.001

1.0

(1.0, 1.0)

0.632

 ESR (>median vs. <median)

1.4

(1.1, 1.9)

0.006

0.9

(0.7, 1.0)

0.116

Overall and ESR-specific cumulative incidence reported as cases per 100,000 background population over the age of 50 years. Incidence for sex reported per 100,000 women or men respectively, and incidence for the different age categories reported per 100,000 population of the same age categories (< 60 years, 60–69 years, 70–79 years and 80+ years). Relative risk calculated according to Poisson regression models for the two timeperiods 1972–1992 and 1993–2012

ESR Erythrocyte sedimentation rate

CI Confidence interval

Reference

  1. 1.
    Brekke LK, et al. Incidence of giant cell arteritis in Western Norway 1972–2012: a retrospective cohort study. Arthritis Res Ther. 2017;19:278.  https://doi.org/10.1186/s13075-017-1479-6.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • L. K. Brekke
    • 1
    • 2
    • 3
    • 6
  • A. P. Diamantopoulos
    • 4
  • B.-T. Fevang
    • 2
    • 3
  • J. Aβmus
    • 5
  • E. Esperø
    • 1
  • C. G. Gjesdal
    • 2
    • 3
  1. 1.Hospital for Rheumatic DiseasesHaugesundNorway
  2. 2.Department of Clinical ScienceUniversity of BergenBergenNorway
  3. 3.Bergen Group of Epidemiology and Biomarkers in Rheumatic Disease (BEaBIRD), Department of RheumatologyHaukeland University HospitalBergenNorway
  4. 4.Martina Hansens HospitalBærumNorway
  5. 5.Centre for Clinical ResearchHaukeland University HospitalBergenNorway
  6. 6.Hospital for Rheumatic Diseases (HSRAS)HaugesundNorway

Personalised recommendations